Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective and Open Label Study With Blind End Point Evaluation on the Effect of Mineralocorticoid Receptor Inhibition on Endothelial Function of the Micro- and Macrovasculature in Patients With Metabolic Syndrome

NCT01319344 is registered in ClinicalTrials.gov with University of Erlangen-Nürnberg Medical School as lead sponsor.

NCT NCT01319344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01319344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective and Open Label Study With Blind End Point Evaluation on the Effect of Mineralocorticoid Receptor Inhibition on Endothelial Function of the Micro- and Macrovasculature in Patients With Metabolic Syndrome
Lead sponsor
University of Erlangen-Nürnberg Medical School
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2010
Completion date
April 30, 2013
Enrollment
42 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

endothelial dysfunction, metabolic syndrome